## Goran Benedeković

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4670909/publications.pdf Version: 2024-02-01



CORAN RENEDEROVIÄT

#	Article	IF	CITATIONS
1	Divergent Synthesis of Cytotoxic Styryl Lactones from <scp>d</scp> -Xylose. The First Total Synthesis of (+)-Crassalactone C. Organic Letters, 2007, 9, 4235-4238.	4.6	38
2	Enantiodivergent synthesis of cytotoxic styryl lactones from d-xylose. The first total synthesis of (+)- and (â~)-crassalactone C. Tetrahedron, 2009, 65, 10596-10607.	1.9	31
3	Design, synthesis and antiproliferative activity of styryl lactones related to (+)-goniofufurone. European Journal of Medicinal Chemistry, 2010, 45, 2876-2883.	5.5	29
4	Enantiodivergent synthesis of muricatacin related lactones from d-xylose based on the latent symmetry concept: preparation of twoÂnovel cytotoxic (+)- and (â^')-muricatacin 7-oxa analogs. Tetrahedron, 2006, 62, 11044-11053.	1.9	26
5	Conformationally constrained goniofufurone mimics as inhibitors of tumour cells growth: Design, synthesis and SAR study. European Journal of Medicinal Chemistry, 2014, 82, 449-458.	5.5	19
6	Divergent synthesis of cytotoxic styryl lactones isolated from Polyalthia crassa. The first total synthesis of crassalactone B. Tetrahedron Letters, 2010, 51, 3426-3429.	1.4	18
7	Design, synthesis and inÂvitro antitumour activity of new goniofufurone and 7- epi -goniofufurone mimics with halogen or azido groups at the C-7 position. European Journal of Medicinal Chemistry, 2017, 128, 13-24.	5.5	17
8	New antitumour agents with α,β-unsaturated δ-lactone scaffold: Synthesis and antiproliferative activity of (â~')-cleistenolide and analogues. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3318-3321.	2.2	16
9	Synthesis and antiproliferative activity of unnatural enantiomers of 7-epi-goniofufurone and crassalactone C. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5178-5181.	2.2	15
10	Design, synthesis and antiproliferative activity of two new heteroannelated (â^')-muricatacin mimics. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5182-5185.	2.2	14
11	Design, synthesis and SAR analysis of antitumour styryl lactones related to (+)-crassalactones B and C. European Journal of Medicinal Chemistry, 2014, 87, 237-247.	5.5	14
12	Novel goniofufurone and 7-epi-goniofufurone mimics from an unexpected titanium-mediated displacement process. Tetrahedron Letters, 2012, 53, 1819-1822.	1.4	13
13	Divergent total synthesis of crassalactones B and C and evaluation ofÂtheir antiproliferative activity. Tetrahedron, 2015, 71, 4581-4589.	1.9	13
14	Heteroannelated (+)-muricatacin mimics: synthesis, antiproliferative properties and structure–activity relationships. Tetrahedron, 2011, 67, 9358-9367.	1.9	11
15	A total synthesis of (+)-oxybiotin from d-arabinose. Tetrahedron, 2004, 60, 5225-5235.	1.9	10
16	Divergent Synthesis of Cytotoxic Styryl Lactones Related to Goniobutenolides A and B, and to Crassalactone D. Organic Letters, 2012, 14, 5956-5959.	4.6	10
17	A comparative study of chromatographic behavior and lipophilicity of selected natural styryl lactones, their derivatives and analogues. European Journal of Pharmaceutical Sciences, 2017, 105, 99-107.	4.0	10
18	Heteroannelated and 7-deoxygenated goniofufurone mimics with antitumour activity: Design, synthesis and preliminary SAR studies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5507-5510.	2.2	9

Goran Benedeković

#	Article	IF	CITATIONS
19	Synthesis and inÂvitro antitumour activity of crassalactone D, its stereoisomers and novel cinnamic ester derivatives. European Journal of Medicinal Chemistry, 2017, 134, 293-303.	5.5	8
20	Stereospecific synthesis of (+)-oxybiotin from d-xylose. Carbohydrate Research, 2002, 337, 459-465.	2.3	7
21	An efficient synthesis of (+)-oxybiotin from d-arabinose. Tetrahedron Letters, 2002, 43, 2281-2284.	1.4	6
22	In vitro antitumor activity, ADME-Tox and 3D-QSAR of synthesized and selected natural styryl lactones. Computational Biology and Chemistry, 2019, 83, 107112.	2.3	6
23	Synthesis and antiproliferative activity of goniobutenolides A and B, 5-halogenated crassalactone D derivatives and the corresponding 7-epimers. European Journal of Medicinal Chemistry, 2016, 108, 594-604.	5.5	5
24	Synthesis, antiproliferative activity and SAR analysis of (â^')-cleistenolide and analogues. European Journal of Medicinal Chemistry, 2020, 202, 112597.	5.5	5
25	Conformationally restricted goniofufurone mimics with halogen, azido or benzoyloxy groups at the C-7 position: Design, synthesis and antiproliferative activity. Tetrahedron, 2018, 74, 4761-4768.	1.9	4
26	Synthesis and antimicrobial activity of (â^')-cleistenolide and analogues. Bioorganic Chemistry, 2021, 106, 104491.	4.1	3
27	Regiochemistry of epoxide ring opening in methyl 2,3-anhydro-4-azido-4-deoxy-α- and β-l-lyxopyranosides. Carbohydrate Research, 2005, 340, 1866-1871.	2.3	2
28	Asymmetric synthesis and biological evaluation of (+)-cardiobutanolide, (â^)-3-deoxycardiobutanolide and analogues as antiproliferative agents. Tetrahedron, 2021, 97, 132408.	1.9	2
29	Design, synthesis and cytotoxic activity of new 6-O-aroyl (â^)-cleistenolide derivatives. Tetrahedron, 2021, 96, 132385.	1.9	2
30	Novel (â^')-goniofufurone mimics: Synthesis, antiproliferative activity and SAR analysis. Journal of the Serbian Chemical Society, 2019, 84, 1345-1353.	0.8	2
31	Chromatographic lipophilicity and pharmacokinetic behavior of some newly synthesized styryl lactone stereoisomers. Acta Periodica Technologica, 2017, , 197-209.	0.2	0